The market for noninvasive ventilation masks is anticipated to grow significantly, reaching an estimated US$ 3.25 billion by 2031, up from US$ 2.05 billion in 2023. This growth represents a compound annual growth rate (CAGR) of 5.9% from 2023 to 2031.
In patients with chronic obstructive pulmonary disease (COPD), invasive ventilation techniques are generally avoided to minimize the risk of complications, including infections and mechanical injuries to the lungs. Noninvasive ventilation masks are favored as they offer respiratory support without the need for intubation.
A reusable noninvasive ventilation (NIV) mask is a flexible, contoured device that covers both the nose and mouth of the patient, connecting to a continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BPAP) machine. This device delivers ambient air or a mixture of medical oxygen and air at a higher pressure to the respiratory system, facilitating non-invasive positive pressure ventilation (NPPV). Several reusable NIV masks are available on the market, such as the PerformaTrak Reusable NIV Mask by Philips and the non-vented complete NIV Face Mask by MSF International. These masks not only help healthcare facilities cut down on consumable costs but also provide patients with a comfortable and non-invasive ventilation experience.
Moreover, Air Liquide Medical Systems, a branch of Air Liquide Healthcare involved in the noninvasive ventilation masks sector, introduced the ALNEST N1 Silent mask in May 2023. This innovative product features Quiet Flow leak technology, which ensures minimal noise levels and gentle diffusion of exhaled air. The Alnest N1 Silent and Alnest N1 are reusable nasal masks equipped with calibrated exhalation orifices, designed for use in both home and hospital settings for patients weighing over 30 kg who require NPPV, such as CPAP or BiPAP therapy. The introduction of advanced technologies, including Quiet Flow leak and innovative headgear, is expected to boost the demand for reusable NIV masks in therapeutic applications.
The adoption of noninvasive ventilation has surged and has become a crucial component in managing both acute and chronic respiratory failure, particularly in home care environments. NIV therapy at home significantly enhances survival rates and quality of life for patients with chronic stable hypercapnia. Patients recovering from acute respiratory failure due to COPD typically need to be monitored for 2-4 weeks after their respiratory acidosis resolves, during which they can be transitioned to home NIV. Additionally, stable COPD patients suffering from chronic hypercapnic respiratory failure can greatly benefit from home-based NIV solutions. These advantages are key drivers for the increasing demand for NIV masks in home care settings.
There is a growing recognition of the necessity for personalized NIV masks, with ongoing efforts aimed at ensuring their long-term use in home environments. In March 2024, a team from Imperial College London and Sheffield Children?s Hospital received funding from Action Medical Research, a children?s charity, and LifeArc, a charitable medical research organization, to develop a fully automated system for creating customized NIV masks for pediatric patients. This initiative, in collaboration with companies like Photocentric and Polymetrix, is expected to present new opportunities for market participants to attract a broader customer base.
Insights Based on End Users
The noninvasive ventilation masks market is categorized by end users into hospitals and clinics, homecare, and other sectors. In 2023, the hospitals and clinics segment dominated the market and is projected to experience the highest CAGR during the period from 2023 to 2031. The rise in medical expenses over recent decades, driven by advancements in healthcare technology, has contributed to this growth. Factors such as improvements in hospital technologies, changes in health insurance policies, economic development across various regions, enhanced reimbursement programs, and the availability of diverse products and services are pivotal in propelling the growth of the noninvasive ventilation masks market within the hospital and clinic segment. The increasing number of hospital admissions due to rising cases of conditions like asthma, COPD, and other chronic respiratory diseases, along with the global presence of hospitals offering NIV services, further supports market expansion. For instance, the Royal Gwent Hospital in Newport, UK, has been providing NIV retrieval services since 2017 to ensure optimal management of patients requiring NIV therapy.
Key sources utilized in the preparation of the noninvasive ventilation masks market report include the United Nations Department of Economic and Social Affairs, the World Health Organization, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the European Center for Disease Prevention and Control.